Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipratropium Bromide for Exercise-Induced Laryngeal Obstruction in Pediatric Patients
NCT07394036Phase 2Not yet recruiting
- Sponsor
- Cook Children's Health Care System
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ipratropium bromide in Exercise-induced laryngeal obstruction (EILO), sponsored by Cook Children's Health Care System. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ipratropium bromide
03
Conditions
Exercise-induced laryngeal obstruction (EILO)
Beyond the preview
Go deeper on NCT07394036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394036.